Question: We know that Tysabri is very effective in reducing relapse frequency and appearing of new lesions, but how effective is it in preventing progression? Or conversion from RRMS to SPMS?
Answer: Several small studies suggest a benefit of Tysabri for secondary progressive MS. A large definitive clinical trial called ASCEND, funded by Biogen Idec, is underway with expected completion by the end of 2014.
PLEASE NOTE: The information/opinions on this site should be used as an information resource only. This information does not create any patient-HCP relationship, and should not be used as a substitute for professional diagnosis and treatment. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition.